Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN

Key Points

• Orographic Financial Advisors LLC initiated a 254,200-share stake in Organon & Co. worth approximately $1.52 million, while institutional investors collectively own 77.43% of the company.
• Organon shares recently traded at $13.54, near their 12-month high of $13.60, but the company’s latest quarterly results fell short of expectations: EPS was $0.71 versus $0.83 estimated, and revenue declined 3.5% year over year to $1.46 billion.
• Analyst sentiment remains cautious despite several upgrades; five analysts rate the stock Hold and two rate it Sell, producing a consensus “Reduce” rating and an $11.40 price target.

Orographic Financial Advisors LLC bought a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 254,200 shares of the company's stock, valued at approximately $1,522,000. Orographic Financial Advisors LLC owned 0.10% of Organon & Co. as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of OGN. Private Management Group Inc. increased its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the period. UBS Group AG raised its position in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company's stock worth $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. Vanguard Group Inc. raised its holdings in Organon & Co. by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company's stock worth $264,690,000 after purchasing an additional 987,979 shares in the last quarter. Brandes Investment Partners LP lifted its position in Organon & Co. by 46.7% during the fourth quarter. Brandes Investment Partners LP now owns 606,499 shares of the company's stock valued at $4,349,000 after acquiring an additional 193,064 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Organon & Co. by 1,062.1% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 254,500 shares of the company's stock worth $1,825,000 after purchasing an additional 232,600 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Insider Buying and Selling

In other news, SVP Lynette Holzbaur purchased 26,448 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average cost of $13.35 per share, with a total value of $353,080.80. Following the completion of the acquisition, the senior vice president directly owned 52,851 shares of the company's stock, valued at approximately $705,560.85. This trade represents a 100.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on OGN shares. Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Weiss Ratings upgraded Organon & Co. from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, July 13th. Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and boosted their target price for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, BNP Paribas Exane restated a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Stock Performance

NYSE:OGN opened at $13.54 on Friday. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.60. The firm has a market capitalization of $3.56 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. The business's fifty day moving average price is $13.47 and its 200 day moving average price is $10.38.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company earned $1.02 EPS. The business's revenue was down 3.5% on a year-over-year basis. On average, sell-side analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.